CDY.AX - Cellmid Limited

ASX - ASX Delayed Price. Currency in AUD

Cellmid Limited

55 Clarence Street
Suite 204 Level 2
Sydney, NSW 2000
Australia
61 2 9221 6830
http://www.cellmid.com.au

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Maria HalaszCEO, MD & Exec. Director496.45kN/AN/A
Mr. Koichiro KoikeManaging Director of Advangen Inc216.72kN/A1957
Dr. Bart WuurmanChief Exec. Officer of Lyramid288kN/AN/A
Dr. Graham RobertsonHead of R&DN/AN/AN/A
Mr. Lee TamplinCompany Sec.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

Corporate Governance

Cellmid Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.